Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eagle Pharmaceuticals (EGRX)

Eagle Pharmaceuticals (EGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Eagle Pharmaceuticals: Q2 Earnings Snapshot

Eagle Pharmaceuticals: Q2 Earnings Snapshot

EGRX : 4.39 (-6.40%)
Eagle Pharmaceuticals (EGRX) Q1 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 5.88% and 3.80%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

EGRX : 4.39 (-6.40%)
SMFL : 0.4850 (+19.37%)
Eagle Pharmaceuticals: Q1 Earnings Snapshot

Eagle Pharmaceuticals: Q1 Earnings Snapshot

EGRX : 4.39 (-6.40%)
Maravai LifeSciences Holdings, Inc. (MRVI) Lags Q1 Earnings and Revenue Estimates

Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of -25% and 0.86%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the...

MRVI : 7.73 (-5.04%)
EGRX : 4.39 (-6.40%)
Chimerix (CMRX) Reports Q1 Loss, Misses Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 0% and 19.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

CMRX : 0.9040 (-1.75%)
EGRX : 4.39 (-6.40%)
Eagle Pharmaceuticals (EGRX) Beats Q4 Earnings and Revenue Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 41.03% and 2.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?...

EGRX : 4.39 (-6.40%)
IMCC : 0.5633 (+8.96%)
Eagle Pharmaceuticals: Q4 Earnings Snapshot

Eagle Pharmaceuticals: Q4 Earnings Snapshot

EGRX : 4.39 (-6.40%)
Should Value Investors Buy Eagle Pharmaceuticals (EGRX) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

EGRX : 4.39 (-6.40%)
Are Investors Undervaluing Eagle Pharmaceuticals (EGRX) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest...

EGRX : 4.39 (-6.40%)
QDEL : 38.71 (-3.95%)
Eagle Pharmaceuticals (EGRX) Q3 Earnings and Revenues Beat Estimates

Eagle Pharmaceuticals (EGRX) delivered earnings and revenue surprises of 33.33% and 11.01%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

EGRX : 4.39 (-6.40%)
ACB : 5.79 (-1.86%)

Barchart Exclusives

This Outperforming Dividend Aristocrat Could Rally Another 22%, Says Analyst
With a track record of 30 years of dividend increases, this industrial stock is also delivering some outsized capital appreciation to shareholders lately. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar